Women - A neglected risk group for atherosclerosis and vascular disease

Scandinavian Cardiovascular Journal

Volumn 37, Issue 1, 2003, Pages 3-12

  Erhardt, Leif R ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CHLORTALIDONE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN; FIBRINOLYTIC AGENT; FLUINDOSTATIN; GESTAGEN; GLYCERYL TRINITRATE; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE; MEVINOLIN; PLACEBO; PRAVASTATIN; SERIC GONADOTROPIN; SIMVASTATIN; UNINDEXED DRUG; VITAMIN D;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET THERAPY; ESTROGEN BLOOD LEVEL; FEMALE; HEALTH HAZARD; HEART INFARCTION; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STROKE; VASCULAR DISEASE;

ARTERIOSCLEROSIS; FEMALE; HUMANS; MENOPAUSE; SEX CHARACTERISTICS; VASCULAR DISEASES;

EID: 0038664139     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430310006965     Document Type: Review

References (131)

1. Pilote L, Hlatky MA. Attitudes of women toward hormone therapy and prevention of heart disease. Am Heart J 1995; 129: 1237-1238.
2. Goldberg RJ, O'Donnell C, Yarzebski J, et al. Sex differences in symptom presentation associated with acute myocardial infarction: A population-based perspective. Am Heart J 1998; 136: 189-195.
3. Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342: 1163-1170.
4. Peltonen M, Lundberg V, Huhtasaari F, Asplund K. Marked improvement in survival after acute myocardial infarction in middle-aged men but not in women. The Northern Sweden MONICA study 1985-94. J Intern Med 2000; 247: 579-587.
5. Lundberg V, Wikstrom B, Bostrom S, Asplund K. Exploring sex differences in case fatality in acute myocardial infarction or coronary death events in the northern Sweden MONICA Project. J Intern Med 2002; 251: 235-244.
6. Schwartz LM, Fisher ES, Tosteson NA, et al. Treatment and health outcomes of women and men in a cohort with coronary artery disease. Arch Intern Med 1997; 157: 1545-1551.
7. Sawaya JI, Jazra C, Eid EV, Sabra RF. Gender differences in the diagnosis and treatment of acute myocardial infarction in Lebanon. J Med Liban 1999; 47: 2-6.
8. Goldberg R, Goff D, Cooper L, et al. Age and sex differences in presentation of symptoms among patients with acute coronary disease: The REACT Trial. Rapid Early Action for Coronary Treatment. Coron Artery Dis 2000; 11: 399-407.
9. Bittner V. Cardiovascular disease in women. J Women's Health 1994; 3: 369-376.
10. Giardina EG. Heart disease in women. Int J Fertil Womens Med 2000; 45: 350-357.
11. Lincoff AM, Califf RM, Ellis SG, et al. Thrombolytic therapy for women with myocardial infarction: Is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group. J Am Coll Cardiol 1993; 22: 1780-1787.
12. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993; 72: 310-313.
13. Kannel WB, Wilson PW, D'Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J 1998; 136: 205-212.
14. Juvela S, Poussa K, Porras M. Factors affecting formation and growth of intracranial aneurysms: A long-term follow-up study. Stroke 2001; 32: 485-491.
15. Poirier P, Despres JP. Exercise in weight management of obesity. Cardiol Clin 2001; 19: 459-470.
16. World Health Organization. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva: World Health Organization, 1998.
17. Anderson JW, Konz EC. Obesity and disease management: Effects of weight loss on comorbid conditions. Obes Res 2001; 9: 326S-334S.
18. Choi BC, Shi F. Risk factors for diabetes mellitus by age and sex: Results of the National Population Health Survey. Diabetologia 2001; 44: 1221-1231.
19. Luft FC. STOPPING at the CAPPP of good HOPE. Nephrol Dial Transplant 2000; 15: 451-452.
20. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255-3264.
21. Lindholm LH, Hansson L, Dahlof B, et al. The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): A progress report. Blood Press 1996; 5: 300-304.
22. Hansson L. Results of the STOP-Hypertension-2 trial. Blood Press Suppl 2000; 2: 17-20.
23. Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18: 1671-1675.
24. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886-1892.
25. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351; 1755-1762.
26. Leys D, Pasquier F. Prevention of dementia: Syst-Eur trial. Lancet 1999; 353: 236-237.
27. Mitchell GF, Pfeffer JM, Pfeffer MA. The heart and conduit vessels in hypertension. Med Clin North Am 1997; 81: 1247-1271.
28. Wilson PW. From hypertension to heart failure: What have we learned? Clin Cardiol 1999; 22: V1-V10.
29. Sundquist J, Winkleby MA, Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: An analysis of NHANES III, 1988-1994. Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 2001; 49: 109-116.
30. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996; 275: 1571-1576.
31. Anastos K, Charney P, Charon RA, et al. Hypertension in women: What is really known? The Women's Caucus. Working Group on Women's Health of the Society of General Internal Medicine. Ann Intern Med 1991; 115: 287-293.
32. Kannel WB. Nutrition and the occurrence and prevention of cardiovascular disease in the elderly. Nutr Rev 1988; 46: 68-78.
33. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-313.
34. Alfredsson L, Hammar N, Fransson E, et al. Job strain and major risk factors for coronary heart disease among employed males and females in a Swedish study on work, lipids and fibrinogen. Scand J Work Environ Health 2002; 28: 238-248.
35. Reuterwall C, Hallqvist J, Ahlborn A, et al. Higher relative, but lower absolute risks of myocardial infarction in women than in men: Analysis of some major risk factors in the SHEEP study. The SHEEP Study Group. J Intern Med 1999; 246: 161-174.
36. Shah PK. Plaque disruption and coronary thrombosis: New insight into pathogenesis and prevention. Clin Cardiol 1997; 20: II38-II44.
37. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997; 20: II3-II10.
38. Misbach J, Ali W. Stroke in Indonesia: A first large prospective hospital-based study of acute stroke in 28 hospitals in Indonesia. J Clin Neurosci 2001; 8: 245-249.
39. Keller KB, Lemberg L. Gender differences in acute coronary events. Am J Crit Care 2000; 9: 207-209.
40. Bittner V. Heart disease in women. Clin Rev Spring 2000: 62-66.
41. Benetos A, Thomas F, Safar ME, Bean KE, Guize L. Should diastolic and systolic blood pressure be considered for cardiovascular risk evaluation: A study in middle-aged men and women. J Am Coll Cardiol 2001; 37: 163-168.
42. Castanho VS, Oliveira LS, Pinheiro HP, Oliveira HC, de Faria EC. Sex differences in risk factors for coronary heart disease: A study in a Brazilian population. BMC Public Health 2001; 1: 3.
43. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA 1993; 269: 3002-3008.
44. Lamon-Fava S, Wilson PW, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1996; 16: 1509-1515.
45. Heart and Stroke Foundation of Canada. Women, heart disease and stroke in Canada: Issues and options. Ottawa: Heart and Stroke Foundation of Canada, 1997.
46. Mosca L, Grundy SM, Judelson D, et al. AHA/ACC scientific statement: Consensus panel statement. Guide to preventive cardiology for women. American Heart Association/American College of Cardiology. J Am Coll Cardiol 1999; 33: 1751-1755.
47. Leinonen KS, Poutanen KS, Mykkanen HM. Rye bread decreases serum total and LDL cholesterol in men with moderately elevated serum cholesterol. J Nutr 2000; 130: 164-170.
48. Lapidus L, Bengtsson C, Larsson B, et al. Distribution of adipose tissue and risk of cardiovascular disease and death: A 12 year follow up of participants in the population study of women in Gothenburg, Sweden. BMJ 1984; 289: 1257-1261.
49. National Center for Health Statistics. Health United States 1998. With socioeconomic status and health chartbook. Hyattsville, MD: National Center for Health Statistics, 1998.
50. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-1445.
51. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. JAMA 1997; 277: 1281-1286.
52. Weiss K, Katzenschlager R, Egert H, Cajka P, Sinzinger H. [Risk factors of atherosclerosis: Results of screening in Southern Austria]. Wien Klin Wochenschr 1991; 103: 566-570.
53. Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery. The SOS Intervention Study. Obes Res 1999; 7: 477-484.
54. Astrup A. Healthy lifestyles in Europe: Prevention of obesity and type II diabetes by diet and physical activity. Public Health Nutr 2001; 4: 499-515.
55. Lundberg V, Stegmayr B, Asplund K, Eliasson M, Huhtasaari F. Diabetes as a risk factor for myocardial infarction: Population and gender perspectives. J Intern Med 1997; 241: 485-492.
56. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 1988; 260: 3456-3460.
57. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-1147.
58. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998; 21: 1236-1239.
59. Goldschmid MG, Barrett-Connor E, Edelstein SL, et al. Dyslipidemia and ischemic heart disease mortality among men and women with diabetes. Circulation 1994; 89: 991-997.
60. Huhtasaari F, Asplund K, Wester PO. Cardiovascular risk factors in the Northern Sweden MONICA Study. Acta Med Scand 1988; 224: 99-108.
61. Gohlke-Barwolf C. Coronary artery disease - is menopause a risk factor? Basic Res Cardiol 2000; 95: 177-183.
62. Stefano GB, Prevot V, Beauvillain JC, et al. Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia. Circulation 2000; 101: 1594-1597.
63. Stefano GB, Prevot V, Beauvillain JC, et al. Estradiol coupling to human monocyte nitric oxide release is dependent on intracellular calcium transients: Evidence for an estrogen surface receptor. J Immunol 1999; 163: 3758-3763.
64. Weiner CP, Lizasoain I, Baylis SA, et al. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994; 91: 5212-5216.
65. Binko J, Majewski H. 17 beta-Estradiol reduces vasoconstriction in endothelium-denuded rat aortas through inducible NOS. Am J Physiol 1998; 274: H853-H859.
66. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811.
67. Sullivan JM, Vander Zwaag R, Lemp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988; 108: 358-363.
68. Akahoshi M, Soda M, Nakashima E, et al. Effects of age at menopause on serum cholesterol, body mass index, and blood pressure. Atherosclerosis 2001; 156: 157-163.
69. Joakimsen O, Bonaa KH, Stensland-Bugge E, Jacobsen BK. Age and sex differences in the distribution and ultrasound morphology of carotid atherosclerosis: The Tromsö Study. Arterioscler Thromb Vasc Biol 1999; 19: 3007-3013.
70. Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1838.
71. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
72. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
73. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733.
74. Cushman M, Meilahn EN, Psaty BM, et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999; 19: 893-899.
75. van Baal WM, Kenemans P, van der Mooren MJ, et al. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999; 81: 925-928.
76. Riese H, Vrijkotte TG, Meijer P, Kluft C, De Geus EJ. Diagnostic strategies for C-reactive protein. BMC Cardiovasc Disord 2002; 2: 9.
77. Salkeld BD, MacAulay JC, Ball RW, Cannon JG. Modulation of body temperature, interleukin-6 and leptin by oral contraceptive use. Neuroimmunomodulation 2001; 9: 319-325.
78. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.
79. Hoibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961-967.
80. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57.
81. Herrington D Results from the Estrogen Replacement and Atherosclerosis study. ACC 49th Annual Scientific Session, Anaheim, CA, 12-15 March 2000.
82. Assaf AR, Carleton RA. The Women's Health Initiative Clinical Trial and Observational Study: History and overview. R I Med 1994; 77: 424-427.
83. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
84. Larsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. Med Clin North Am 1994; 78: 225-245.
85. Kastelein JJ, Isaacsohn JL, Ose L, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000; 86: 221-223.
86. Illingworth DR, Crouse JR, 3rd, Hunninghake DB, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 2001; 17: 43-50.
87. Legato MJ. Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: Implications for therapy. Am J Cardiol 2000; 86: 15L-18L.
88. Gotto AM, Jr. Cholesterol management in theory and practice. Circulation 1997; 96: 4424-4430.
89. Havel RJ. Analysis of angiographic trial data in women. Drugs 1994; 47: 11-15.
90. Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
91. Collins R, Results from the Heart Protection Study. Presented at the American Heart Association's Scientific Sessions, Los Angeles, CA, 2001.
92. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32: 140-146.
93. Quan A, Kerlikowske K, Gueyffier F, Boissel JP. Efficacy of treating hypertension in women. J Gen Intern Med 1999; 14: 718-729.
94. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
95. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
96. Australian National Blood Pressure Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet 1980; 1: 1261-1267.
97. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. Medical Research Council Working Party. BMJ 1985; 291: 97-104.
98. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349-1354.
99. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285.
100. Schirmer H, Lunde P, Rasmussen K. Prevalence of left ventricular hypertrophy in a general population; The Tromsö Study. Eur Heart J 1999; 20: 429-438.
101. MRC working party. MRC trial of treatment of hypertension in older adults. BMJ 1992; 304: 405-412.
102. Kastarinen MJ, Salomaa VV, Vartiainen EA, et al. Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997. J Hypertens 1998; 16: 1379-1387.
103. Sanada M, Higashi Y, Nakagawa K, et al. Relationship between the angiotensin-converting enzyme genotype and the forearm vasodilator response to estrogen replacement therapy in postmenopausal women. J Am Coll Cardiol 2001; 37: 1529-1535.
104. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
105. Hermans WR, Rensing BJ, Foley DP, et al. Therapeutic dissection after successful coronary balloon angioplasty: No influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis). J Am Coll Cardiol 1992; 20: 767-780.
106. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995; 25: 362-369.
107. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-242.
108. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
109. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
110. Fogari R, de Gasparo M. Addressing those two that go together: The Angiotensin II receptors and their role in blood-flow regulation. Blood Press 2001; 10: 6-15.
111. Markham A, Goa KL, Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299-311.
112. Bodin F. Pharmacological and clinical profile of valsartan. J Hypertens 2000; 18: S1-S7.
113. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 797-810.
114. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997; 11: 483-489.
115. Sironi L, Calvio AM, Arnaboldi L, et al. Effect of valsartan on Angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells. Hypertension 2001; 37: 961-966.
116. Feng T, Ying W, Hua T, Ji Y, de Gasparo M. Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade. JRAAS 2001; 2: 19-24.
117. Hocher B, Thone-Reineke C, Rohmeiss P, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99: 1380-1389.
118. de Gasparo M, Hess P, Nuesslein-Hildesheim B, Bruneval P, Clozel JP. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. JRAAS 2000; 1: 151-158.
119. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: The VAL-PREST trial. J Invasive Cardiol 2001; 13: 93-97.
120. Remme WJ, Swedberg K. for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560.
121. Latini R, Anand I, Judd D, Cohn J, for the Val-HeFT investigators. Data presented at 74th Scientific Sessions of the American Heart Association, Anaheim, CA, 2001.
122. Wieczorek S, Bailly K, Thomas P. Clinical evaluation of the Triabe B-type natriuretic peptide assay for point of care testing of patients with congestive heart failure. Clin Chem 2001; 46: A77.
123. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141: 367-374.
124. Kjeldsen SE, Dahlof B, Devereux RB, et al. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study. Losartan Intervention For Endpoint. Am J Hypertens 2000; 13: 899-906.
125. Dahlöf B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
126. Lindholm L, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 369: 1004-1010.
127. Kjeldsen S, Julius S, Brunner H, et al. Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE Trial. Blood Press 2001; 10: 83-91.
128. Njolstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. Circulation 1996; 93: 450-456.
129. Johansson I, Wikman AA, Hallmans G. Changes in food selection in northern Sweden - the MONICA surveys 1986 and 1990. Scand J Nutr 1994; 38: 56-61.
130. Peltonen M, Rosen M, Lundberg V, Asplund K. Social patterning of myocardial infarction and stroke in Sweden: Incidence and survival. Am J Epidemiol 2000; 151: 283-292.
131. Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol 1997; 30: 1417-1419.